The cost-effectiveness of hepatitis A vaccination in patients with chronic hepatitis C

Myers, Robert P.; Gregor, James C.; Marotta, Paul

doi:10.1053/he.2000.5719

Cited by 53 publications

(14 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Strong evidence indicates that influenza vaccination is cost-effective or even cost-saving in high-risk adults (28), and on this basis the vaccination of CLD patients seems reasonable. Three economic assessments have considered hepatitis A vaccination for chronic hepatitis C patients (29)(30)(31). Two report acceptable cost effectiveness ratios (30,31).…”

Section: Discussionmentioning

confidence: 99%

Immunization Needs of Chronic Liver Disease Patients Seen in Primary Care Versus Specialist Settings

Jacobs¹,

Meyerhoff²,

Saab³

2005

Dig Dis Sci

View full text Add to dashboard Cite

Chronic liver disease patients may benefit from certain vaccines, but their immunization coverage levels have not been widely studied. We examined the serologic and vaccination status of 693 chronic liver disease patients from 37 primary care and specialist centers. Patients in primary care had more often received influenza (47 versus 32%; P < .001) and pneumococcal (39 versus 19%; P < .001) vaccines. Among patients without documented prior exposure, those seeing specialists had more often completed hepatitis A (28 versus 5%; P < .001) and hepatitis B (29 versus 14%; P < .001) vaccination. Coverage was higher in centers with a policy of vaccinating on-site, among non-Hispanic whites, and among patients with hepatitis C and cirrhosis. In summary, most patients were unprotected against one or more vaccine preventable diseases. The higher coverage rates evident in centers vaccinating on-site suggests a breakdown may occur when patients are referred to alternative vaccination venues.

show abstract

Section: Discussionmentioning

confidence: 99%

Immunization Needs of Chronic Liver Disease Patients Seen in Primary Care Versus Specialist Settings

Jacobs¹,

Meyerhoff²,

Saab³

2005

Dig Dis Sci

View full text Add to dashboard Cite

show abstract

“…28 We did not consider costs of hepatitis A vaccination adverse events, which have previously been estimated at Ͻ$1 per vaccination series. 46 We assumed that 98 and 99% of children would produce protective concentrations of hepatitis A antibody after the first and second vaccine dose, respectively. 15 Loss of immunity in subsequent years was estimated based on published models of antibody persistence.…”

Section: Methodsmentioning

confidence: 99%

Regional variation in the cost effectiveness of childhood hepatitis A immunization

Jacobs

Greenberg

Koff

et al. 2003

The Pediatric Infectious Disease Journal

View full text Add to dashboard Cite

show abstract

“…19 Economic analyses generally support these recommendations (Table 6), showing a degree of cost-effectiveness comparable with that of other vaccines in children living both in highly endemic areas of the United States and in the nation as a whole, 1,32,42 as well as cost-effectiveness well within accepted boundaries 28 for adolescents 31 and adults in several high-risk categories. 20,36,[38][39][40][46][47][48][49][50] Moreover, the combination vaccine for hepatitis A and hepatitis B may further improve the cost-effectiveness of vaccination programs. 42,69 In summary, this review of universal immunization against hepatitis A in children, adolescents, and high-risk adults in developed countries supports the cost-effectiveness of implementing ACIP recommendations regarding the use of these vaccines in the United States.…”

Section: Discussionmentioning

confidence: 99%

Cost-effectiveness of hepatitis A vaccination in children, adolescents, and adults

Rosenthal

2003

Hepatology

View full text Add to dashboard Cite

Hepatitis A is a major public health problem in the United States and other developed countries, largely because decreased natural immunity allows for increased susceptibility. To evaluate the cost-effectiveness of routine vaccination of children, adolescents, and certain high-risk adults against hepatitis A, economic analyses of hepatitis A vaccination were identified through searches of MEDLINE, EMBASE, and BIOSIS (February, 1992, to December, 2001) for studies, reviews, editorials, and letters from peer-reviewed journals published in English, French, German, Italian, or Spanish. Experts were also contacted. Articles conforming to accepted standards of quality for health-economic studies were used to compile data on vaccination of children, and results were synthesized in a narrative review. This review of economic analyses of vaccine use in several developed countries shows cost-effectiveness comparable with that of other vaccines in children and within accepted boundaries for adolescents and high-risk adults. (HEPATOLOGY 2003;37:44-51.)

show abstract

The cost-effectiveness of hepatitis A vaccination in patients with chronic hepatitis C

Cited by 53 publications

References 31 publications

Immunization Needs of Chronic Liver Disease Patients Seen in Primary Care Versus Specialist Settings

Immunization Needs of Chronic Liver Disease Patients Seen in Primary Care Versus Specialist Settings

Regional variation in the cost effectiveness of childhood hepatitis A immunization

Cost-effectiveness of hepatitis A vaccination in children, adolescents, and adults

Contact Info

Product

Resources

About